Even though the activities of FGF21 in these types of cancers have not been explored yet, elevated serum levels of FGF21 were reported in the early stages of breast cancer 106 but significantly reduced following 12 months of hormonal therapy 107. This evidence concerns the gene FGF21 and breast carcinoma.